Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen

Substantial evidence underscores the clinical efficacy of inhibiting CYP17A1-mediated androgen biosynthesis by abiraterone for treatment of prostate oncology. Previous structural analysis and in vitro assays revealed inconsistencies surrounding the nature and potency of CYP17A1 inhibition by abirate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Pharmacol Exp Ther
Main Authors: Cheong, Eleanor Jing Yi, Nair, Pramod C., Neo, Rebecca Wan Yi, Tu, Ho Thanh, Lin, Fu, Chiong, Edmund, Esuvaranathan, Kesavan, Fan, Hao, Szmulewitz, Russell Z., Peer, Cody J., Figg, William D., Chai, Christina Li Lin, Miners, John O., Chan, Eric Chun Yong
Formato: Artigo
Idioma:Inglês
Publicado em: The American Society for Pharmacology and Experimental Therapeutics 2020
Assuntos:
Drug Discovery and Translational Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7469252/
https://ncbi.nlm.nih.gov/pubmed/32554434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.120.265868
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados